HEATH LINDSEY: Open Payments
NPI 1578048708 · SHOW LOW, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$922 in 49 payments from 12 companies in 2025. Trend: 2023 $362 · 2024 $438 · 2025 $922
Food & beverage: $922
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 10 | $195 |
| Teva Pharmaceuticals USA, Inc. | 11 | $167 |
| Otsuka America Pharmaceutical, Inc. | 9 | $166 |
| Janssen Pharmaceuticals, Inc | 4 | $103 |
| GlaxoSmithKline, LLC. | 4 | $76 |
| Alkermes, Inc. | 3 | $72 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
| AstraZeneca Pharmaceuticals LP | 2 | $32 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $27 |
| Exact Sciences Corporation | 1 | $20 |
Products named: INGREZZA, ABILIFY MAINTENA, AUSTEDO XR, TRELEGY ELLIPTA, LYBALVI, SPRAVATO, INVEGA SUSTENNA, UZEDY.
Industry payments across AZ — which companies pay providers there.
